samsung biologics

Why Samsung BioLogics’ IPO was such a hit

Investors piled into the biologic drug manufacturer’s listing despite a young corporate history and an unimpressive track record of generating profits.
October 31, 2016

Samsung BioLogics gauges demand for IPO

South Korea’s biggest conglomerate sets out with ambitious plans to raise as much as $2 billion from the listing of its contract drug unit on the Korean stock market.
October 04, 2016